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RCAS1, which acts as a ligand for a putative receptor on immune cells such as peripheral lymphocytes and natural killer cells, is
strongly expressed in human cancers. RCAS1 can induce these cells to undergo apoptotic cell death, which suggests that RCAS1
expression may prohibit the stromal reaction occurring in a tumour. To clarify the clinical significance of RCAS1 expression in uterine
endometrial cancer, we analysed the association between RCAS1 expression and clinicopathologic variables by statistical methods.
With the use of immunohistochemical techniques, we performed a retrospective study of RCAS1 expression in resected tumour
tissue from 147 patients with uterine endometrial cancer. We evaluated the statistical correlation between RCAS1 expression and
clinicopathologic variables. RCAS1 was expressed in 106 of 147 patients with uterine endometrial cancer; 30 of these 147 patients
showed RCAS1 overexpression. Overexpression of RCAS1 was significantly correlated with age at surgery, stage, extent of
myometrial invasion, and positive peritoneal cytologic results. Multivariate analysis revealed that RCAS1 expression and metastasis
were clinically significant prognostic factors for the overall survival. These findings indicated that analysis for RCAS1 expression can
provide crucial information about the clinical behaviour of uterine endometrial cancer, which may be valuable for the management of
patients with this disease.
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Uterine endometrial cancer is one of the most frequently
diagnosed gynaecologic malignancies in Western countries.
Approximately 38300 new cases and 6600 deaths caused by
uterine endometrial cancer occurred in the year 2001 in the US
(American Cancer Society, 2002). In Japan, the incidence of uterine
endometrial cancer has been reported as 22% of all uterine
malignancies, with 1133 deaths caused by this disease in 2001
(Japan Society of Obstetrics and Gynecology, 1998; National
Cancer Center, 2002). The best prophylaxis for uterine endometrial
cancer and the precursors of this disease is thought to be the early
detection. The risk of recurrence is directly related to surgical
stage; extension of tumour cell invasion into the cervix; positive
peritoneal cytologic results; metastases including involvement of
lymph nodes, adnexa, and other organs; degree of myometrial
invasion; and tumour differentiation (DiSaia and Creasman, 1997).
Survival of patients with uterine endometrial cancer thus depends
on these clinicopathologic factors.
Alterations in the transforming genes including K-ras and c-
erbB2/neu oncogenes and the p53 and PTEN tumour suppressor
genes are associated with the development of uterine endometrial
cancer (Enomoto et al, 1990; Kohler et al, 1992; Bancher-Todesca
et al, 1998; Maxwell et al, 1998; Esteller et al, 1999). Of various
molecular markers, the following have been reported as possible
prognostic factors for this disease: angiogenetic factors, epidermal
growth factor receptor (EGFR), hormonal receptors including
Oestrogen receptor and progesterone receptor, and motility-
related protein 1 (MRP1)/CD9 (Chambers et al, 1988; Ingram
et al, 1989; Morgan et al, 1996; Ebert et al, 2000; Miyamoto et al,
2001; Sivridis, 2001). Although several molecular alterations in
uterine endometrial cancer have been identified, few reports have
demonstrated the significant molecules in a large number of
clinical samples. To improve the clinical outcome for this disease,
these crucial molecules should be identified so as to allow their use
as clinical prognostic factors.
RCAS1 (receptor-binding cancer antigen expressed on SiSo
cells) is a type II membrane protein able to form oligomers
through a coiled-coil structure in its C-terminal portion (Naka-
shima et al, 1999). RCAS1 acts as a ligand for a putative receptor
present in various human cell lines and on normal peripheral
lymphocytes. RCAS1 inhibits the in vitro growth of receptor-
expressing cells and induces apoptotic cell death. RCAS1 was
strongly expressed in uterine and ovarian malignancies (Sonoda
et al, 1996; Razvi et al, 1999). In different human cancers, RCAS1
expression has been associated with clinical outcome. RCAS1
expression was significantly related to the overall survival of
patients with uterine cervical adenocarcinoma or non-small-cell
Received 31 December 2002; revised 30 April 2003; accepted 7 May
2003
*Correspondence: Dr S Miyamoto, Department of Obstetrics and
Gynecology, Graduate School of Medical Sciences, Kyushu University,
Maidashi, Higashi-ku, Fukuoka, Fukuoka 812-8582, Japan;
E-mail: smiya@gynob.med.kyushu-u.ac.jp
British Journal of Cancer (2003) 89, 546–551
& 2003 Cancer Research UK All rights reserved 0007– 0920/03 $25.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
ylung carcinoma (Kaku et al, 1999; Iwasaki et al, 2000; Izumi et al,
2001). RCAS1 expression has also been reported to correlate with
tumour progression or the invasive tendency of uterine cervical,
gastric, skin, and hepatocellular carcinomas (Sonoda et al, 1998;
Kubokawa et al, 2001; Noguchi et al, 2001; Takahashi et al, 2001).
Thus, RCAS1 may play a pivotal role in the aggressive behaviour of
a tumour in humans. We previously reported that RCAS1
expression increased during carcinogenesis of uterine endometrial
cancer (Sonoda et al, 2000). To clarify the clinical prognostic
significance of RCAS1 expression in uterine endometrial cancer,
we analysed the univariate and multivariate association between
RCAS1 expression and clinicopathologic variables in 147 patients
with this disease.
MATERIALS AND METHODS
Patients and surgical specimens
All the patients with uterine endometrial cancer in this study had
undergone surgery between January 1979 and February 1999 at the
Department of Obstetrics and Gynecology, Kyushu University
Hospital. The mean age of all patients was 54.3 years, with a range
of 27–82 years. The mean duration of follow-up for all patients
was 195.7 months, with a range of 4–618 months. The histologic
subtype of all cases was endometrioid adenocarcinoma. Clinical
staging of the 147 cases was as follows: 77, 25, 35, and 10 cases were
classified as stages I, II, III, and IV, respectively. The specimens in
this study were graded according to the 1988 International
Federation of Gynecology and Obstetrics criteria. Slides of both
curettage specimens of uterine endometrium and hysterectomy
specimens were available for this study. All specimens were fixed,
embedded in paraffin, and stained with haematoxylin and eosin.
Histologic methods were used for evaluation of the slides of the
specimens to determine the grade of the carcinoma, depth of
myometrial invasion, cervical invasion, invasion of the lymph–
vascular space, and metastases of lymph nodes and other organs.
With regard to metastases, 22 cases had lymph node metastases, 12
cases had adnexal metastases, four cases had rectal metastases, one
case had bone metastases, and two cases had multiple metastases.
A peritoneal washing was also evaluated by cytologic methods.
In this study, 50 patients were treated by surgery alone (total
abdominal hysterectomy, bilateral salpingo-oophorectomy, pelvic
and para-aortic lymphadenectomy). After the operation, certain
patients received additional therapy: 39, 15, and 14 cases received
radiation, hormonal therapy, and platinum-based chemotherapy,
respectively; and 29 cases received a combination of surgery,
radiation, and hormonal treatment or platinum-based chemother-
apy. The overall survival time was defined as the time from the
surgery date to the final date of observation in this study (31
March 2002) or the time from the surgery date to the date at death
caused by the cancer.
Tissue specimens of uterine endometrial hyperplasia were
obtained from 30 patients at surgery. These 30 endometrial
hyperplasia samples included 10 cases each of simple, complex,
and atypical hyperplasias. Normal uterine endometrial tissue
specimens were also obtained at surgery from 30 Japanese patients:
10 cases in the follicular phase of the menstrual cycle, 10 cases in
the secretory phase of the menstrual cycle, and 10 cases in the
postmenopausal state.
Informed consent was obtained from all patients.
Immunohistochemistry
For immunohistochemical analyses, one or two representative
sections were selected for each case, and the streptavidin–biotin
method was used for formalin-fixed, paraffin-embedded speci-
mens (Hsu et al, 1981). Sections 4-mm thick were cut from
paraffin-embedded blocks. Endogenous peroxidase was blocked
with 3% hydrogen peroxidase for 5min. The slides were then
washed twice in Tris-buffered saline (TBS) and were incubated
with normal goat serum diluted in a cell staining buffer (TBS
containing 0.1% bovine serum albumin and 0.01% sodium azide)
for 30min. Next, mouse anti-human RCAS1 monoclonal antibody
was applied, and the slides were incubated in a moist chamber for
30min. After two additional washes, the sections were incubated
for 30min with biotinylated second antibody (goat anti-mouse
immunoglobulins; DAKO, Glostrup, Denmark). The sections were
washed three times in TBS and were incubated with avidin-
biotinylated peroxidase complex (Strept ABC complex/horseradish
peroxidase; DAKO) for 30min. After three additional washes in
TBS, a 3,30-diaminobenzine tetrahydrochloride working solution
was applied. The sections were then counterstained in haematox-
ylin and mounted in Permount. The entire procedure was
performed at room temperature. Negative controls were treated
in the same way, but anti-RCAS1 monoclonal antibody was
replaced by mouse IgM.
The 30 specimens of normal endometrium and 34 specimens of
endometrial cancer were also stained with anti-TNF-a (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and anti-Fas-L (Histofine,
Nichirei, Japan) monoclonal antibodies, and the relation between
the expression of RCAS1 and that of TNF-a or Fas-L was evaluated.
Specimens classified on the basis of immunohistochemical
results
The immunohistochemical expression of RCAS1, TNF-a, and Fas-L
was reviewed independently by two observers (K Sonoda and S
Miyamoto) who had no knowledge of the clinicopathologic data.
Five representative fields were examined, and a total of 1000
tumour cells (200 for each field) was counted via a microscope
with a high-power field ( 400) objective. The observers counted
each slide twice, so that there were four counts for each slide, and
the average of the four scores was recorded. Criteria for scoring the
overall extent of immunoreaction were as follows: more than 50%
positive cells¼overexpression, from 25 to 50% positive
cells¼positive expression, and less than 25% positive
cells¼normal expression.
For evaluation of TNF-a and Fas-L expression, we examined 30
specimens of normal endometrium and 34 specimens of endo-
metrial cancer. The latter consisted of 12 cases with normal
expression of RCAS1, five cases with positive expression of RCAS1,
and 17 cases with overexpression of RCAS1. The numbers of cells
positive for TNF-a and Fas-L expression among the 1000 tumour
cells in the tissue sections were counted.
Statistical analysis
The Fisher exact test, for each clinicopathologic factor and the
expression levels of TNF-a and Fas-L, was used to find
the significant factors that affected the expression of RCAS1 as
univariate variables. The Mann–Whitney test was performed
to check the equality of the distribution of age at surgery between
the group showing RCAS1 overexpression and the other groups
of RCAS1. The Overall survival curves were estimated by
using Kaplan–Meier methods and were analysed by the log-rank
test. Cox’s proportional hazards regression analysis for the
overall survival was used to select a set of prognostic factors from
the nine variables, which were RCAS1 plus eight factors given in
the first column of Table 1. Likelihood ratio tests, with a
significance level of 0.05, were used to enter or remove factors at
each step in the forward stepwise method. Statistical analysis was
performed with the BMDP 3D, 2L computer package (BMDP, Los
Angeles, CA, USA) and Statxact (Cytel Software Co., Cambridge,
MA, USA).
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Immunohistochemical detection of RCAS1 in endometrial
cancer
Diffuse staining for RCAS1 was observed both in the cytoplasm
and on the cell membrane of cancer cells (Figure 1). RCAS1
expression was detected in eight of 30 cases with normal uterine
endometrium. Seven of these eight cases showed positive staining
in 5–25% of cells; only one case showed positive staining in 25–
50% of cells. In specimens of uterine endometrial hyperplasia,
RCAS1 was expressed in less than 25% of cells in eight of 30
patients; positive RCAS1 staining in 25–50% of cells was found in
three patients. The remaining 19 patients with endometrial
hyperplasia demonstrated no expression of RCAS1. Among the
147 patients with uterine endometrial cancer, 51, 25, and 30 cases
showed positive RCAS1 expression in 5–25, 26–50, and 51–100%
of cells, respectively.
Association of RCAS1 expression level with overall survival
The overall survival curves according to the level of RCAS1
expression are shown in Figure 2 for 147 patients with endometrial
adenocarcinoma. Patients with overexpression of RCAS1 had a
significantly less favourable prognosis than those with normal
expression and those with positive expression of RCAS1. The
overall survival rates in the groups with normal expression,
positive expression, and overexpression of RCAS1 were 96, 78, and
40%, respectively. The clinical outcome in patients with over-
expression of RCAS1 was regarded as significantly poor
(Po0.0001).
Relation between immunodetected RCAS1 and
clinicopathologic data
To evaluate the clinical significance of overexpression of RCAS1,
we used statistical methods to analyse the relation between RCAS1
expression level and clinicopathologic variables. As shown in
Table 1, the Fisher exact test for the group showing RCAS1
overexpression and the group showing the other RCAS1 expres-
sion levels revealed no statistically significant relation for the
histologic grade, degree of cervical stromal invasion, degree of
lymph–vascular space invasion, and metastases in patients with
uterine endometrial cancer. Using the Mann–Whitney test, we
found a significant difference in age at surgery between these two
groups (Po0.0001). There were significant associations between
overexpression of RCAS1 and surgical stage (P¼0.009), extent of
myometrial invasion (P¼0.043), and peritoneal cytologic results
(P¼0.017).
Table 1 Relation between RCAS1 expression and clinicopathologic data
RCAS1
expression
a
Clinicopathologic
variables
Others
(n5117)
Overexpression
(n530)
P-value
Age (years; mean7s.d.) 52.779.6 60.879.2 o0.0001
Surgical stage 0.009
I6 9 8
II 16 9
III 26 9
IV 6 4
Histologic grade 0.271
G1 77 15
G2 20 8
G3 20 7
Myometrial invasion (%) 0.043
o50 78 14
450 39 16
Cervical stromal invasion
Negative 115 30 0.470
Positive 2 0
Lymph – vascular space invasion 0.097
Negative 88 18
Positive 29 12
Metastases
b 0.456
Negative 86 20
Positive 31 10
Peritoneal cytologic results 0.017
Negative 100 20
Positive 17 10
aCriteria for scoring RCAS1 expression were as follows: overexpression¼more than
50% RCAS1-positive cells; others¼from 0 to 50% RCAS1-positive cells.
bMetastases included involvement of lymph nodes and adnexa and metastases in
other organs.
Figure 1 Immunohistochemical staining for RCAS1. This specimen
showed RCAS1 overexpression. RCAS1 existed both in the cytoplasm and
on the cell membrane of uterine endometrial adenocarcinoma cells.
RCAS1 was also detected in the glandular lumen of the tumour cells
(counterstained with haematoxylin; original magnification, (A)  100, bar
50mm; (B)  200, bar 25mm).
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Table 2 shows the results of Cox’s proportional hazards regression
analysis performed with a stepwise method. Multivariate analysis
suggested that overexpression of RCAS1 and metastasis were
significant prognostic factors for the overall survival in patients
with uterine endometrial cancer. However, only two of 147 patients
with endometrial cancer had cervical stromal invasion, and they
were alive at the final date of observation in this study (31 March
2002). Therefore, cervical stromal invasion was regarded as a
clinically insignificant factor because of the small number of cases.
Relation between RCAS1 and TNF-a or Fas-L expression
level
In cases with normal endometrium, the numbers of cells positive
for TNF-a and Fas-L expression were 32.2711. 2 and 22.6712.3
(mean7s.d.), respectively. All cases showed less than 10%
expression of TNF-a and Fas-L. In cancer patients with normal
expression, positive expression, and overexpression of RCAS1, the
numbers of cells positive for TNF-a expression were 35.2712.2,
29.2712.5, and 30.4714.2, respectively. The corresponding
numbers for Fas-L expression in these groups were 21.2710.3,
25.2711.5, and 20.6714.2. All these patients also showed less than
10% expression of TNF-a and Fas-L. These results indicated that
RCAS1 expression had no association with TNF-a and Fas-L
expression levels.
DISCUSSION
In this study, a significant association was found between RCAS1
expression level and surgical stage (P¼0.009), extent of myome-
trial invasion (P¼0.043), and peritoneal cytologic results
(P¼0.017). These findings suggested that RCAS1 may have a role
in the invasive properties of endometrial cancer. Patients with
overexpression of RCAS1 had a significantly poorer prognosis than
those with normal RCAS1 expression and those with positive
RCAS1 expression. Multivariate analysis indicated that over-
expression of RCAS1 and metastasis were independent significant
prognostic factors for overall survival in patients with uterine
endometrial cancer.
Fas-L-expressing carcinomas induce apoptosis in lymphocytes
with Fas expression (O’Connell et al, 1996; Gastman et al, 1999).
The inverse correlation between Fas-L expression and the number
of CD8-positive tumour-infiltrating lymphocytes are reported in
several malignancies (Ohno et al, 2000; Zietz et al, 2001). It has
been thought that cancer cells expressing Fas-L have an advantage
to evade antitumour immune surveillance in the course of an
apoptotic tumour counterattack mechanism. In cultured cancer
cells that express RCAS1, RCAS1 is secreted into the medium
(Sonoda et al, 1996) RCAS1 is cleaved proteolytically by 12-O-
tetradecanoylphorbol 13-acetate (TPA) as TNF-a and Fas-L are
processed (manuscript in preparation). It is plausible that RCAS1
is secreted from the cancer cells with overexpression of RCAS1.
RCAS1 induces apoptosis of lymphocytes by binding to a putative
RCAS1 receptor (Nakashima et al, 1999). In addition, RCAS1
expression is associated with the number of apoptotic lymphocytes
adjacent tumour cells in lung cancer and Hodgkin’s disease
(Iwasaki et al, 2000; Ohshima et al, 2001), and RCAS1 expression is
inversely related with the degree of intratumoral infiltration of
lymphocytes (Suzuki et al, 2001). In this study, TNF-a and Fas-L
were little expressed in endometrial cancers. According to these
evidences, lymphocyte apoptosis is possibly induced by the
expression of RCAS1 in stromal tissue surrounding cancer cells
with overexpression of RCAS1. Thus, RCAS1 may facilitate the
invasion of cancer cells into connective tissue in endometrial
cancer, because of an inhibition of the stromal reaction occurring
in a tumour.
Reportedly, RCAS1 is localised to chromosome 8q23, and its
expression is induced by oestrogen (Ikeda et al, 2000). Oestrogen
receptor is expressed in both normal and hyperplastic uterine
endometrial tissues (Lecce et al, 2001). In this study, RCAS1 was
detected in less than 25% of cells in both of these uterine
endometrial tissues. Therefore, RCAS1 expression in normal and
hyperplastic uterine endometrial tissues may be mediated by
activation of the Oestrogen receptor. However, a loss of Oestrogen
receptor and progesterone receptor is associated with a clinically
poor outcome (Niwa et al, 1999; Kounelis et al, 2000; Sivridis et al,
2001). Mediation by stimulation of Oestrogen production cannot
be the primary explanation for the excess of RCAS1 in uterine
endometrial cancer.
In principle, apoptotic factors including TNF-a and Fas-L are
secreted by proteolytic processing and induce programmed cell
death of target cells (Nagata, 1997; Baud and Karin, 2001). RCAS1
is also cleaved proteolytically. The ectodomain shedding of these
factors is induced by addition of peptide growth factors and
activation of mitogen-activated protein kinase (Fan and Derynck,
1999; Nath et al, 2001; Umata et al, 2001). In addition, expression
of EGFR and HER-2/neu is associated with the aggressiveness of an
uterine endometrial tumour, and expression of PCNA and Ki67 is
correlated with clinical outcome (Khalifa et al, 1994; Niikura et al,
1995; Nordstrom et al, 1996; Fujiwaki et al, 1999; Rolitsky et al,
1999). According to these previous studies, the activation of
mitogenic signals may be involved in the aggressive behaviour of
uterine endometrial cancer. In cancer cells with aggressive
potential, therefore, the excess of RCAS1 may have a role in the
accelerated turnover of RCAS1 through ectodomain shedding.
However, the molecular mechanisms for RCAS1 expression in
aggressive endometrial cancer have remained obscure.
Our results presented here are the first to demonstrate that
analysis of expression levels of RCAS1 can provide clinical
Figure 2 Overall survival of 147 patients with endometrial adenocarci-
noma as related to RCAS1 expression (Kaplan–Meier estimates). The P-
value was determined with the log-rank test. Patients with RCAS1
overexpression had a poorer survival than those with normal RCAS1
expression and those with positive RCAS1 expression (Po0.0001).
Table 2 Results of Cox’s proportional hazards regression analysis
Prognostic factor
Relative
risk
95% confidence
interval P-value
RCAS1 (0: reduced, 1: overexpression) 8.191 3.990 – 16.816 o0.0001
Metastasis (0: negative, 1: positive) 4.464 2.280 – 8.743 o0.0001
Cervical stromal invasion
(0: negative, 1: positive)
2.542 1.331 – 4.854 0.0047
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endometrial cancer. Thus, evaluation of not only clinicopathologic
parameters but also RCAS1 expression level may have clinical
value for management of endometrial cancer patients.
In previous studies, RCAS1 expression was associated with
poorer clinical prognosis for uterine cervical adenocarcinoma and
non-small-cell lung carcinoma (Kaku et al, 1999; Iwasaki et al,
2000; Izumi et al, 2001). RCAS1 expression has also been reported
to correlate with tumour progression or the invasive tendency of
uterine cervical, gastric, skin, and hepatocellular carcinomas
(Sonoda et al, 1998; Kubokawa et al, 2001; Noguchi et al, 2001;
Takahashi et al, 2001). The development of therapeutic tools
against RCAS1 would allow us to explore novel targeting therapy in
human cancers including uterine endometrial cancer.
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